These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31849277)

  • 1. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update.
    Ling SF; Bluett J
    Pharmacogenomics; 2020 Jan; 21(1):3-6. PubMed ID: 31849277
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis.
    Jekic B; Maksimovic N; Damnjanovic T
    Pharmacogenomics; 2019 Nov; 20(17):1235-1245. PubMed ID: 31648623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T
    J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
    [No Abstract]   [Full Text] [Related]  

  • 5. Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort.
    Owen SA; Lunt M; Hider SL; Bruce IN; Barton A; Thomson W
    Arthritis Rheum; 2010 Dec; 62(12):3827-9. PubMed ID: 20848569
    [No Abstract]   [Full Text] [Related]  

  • 6. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?
    Ranganathan P; Eisen S; Yokoyama WM; McLeod HL
    Ann Rheum Dis; 2003 Jan; 62(1):4-9. PubMed ID: 12480661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision Medicine in Rheumatoid Arthritis.
    Bluett J; Barton A
    Rheum Dis Clin North Am; 2017 Aug; 43(3):377-387. PubMed ID: 28711140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
    Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF
    Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race and methotrexate pharmacogenetics in rheumatoid arthritis.
    Ranganathan P; McLeod H
    J Rheumatol; 2010 May; 37(5):1064; author reply 1065. PubMed ID: 20439524
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics.
    Conti V; Corbi G; Costantino M; De Bellis E; Manzo V; Sellitto C; Stefanelli B; Colucci F; Filippelli A
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33327600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rheumatoid arthritis and polycythemia vera JAK2 negative association: Polycythemia may be worsening under methotrexate?].
    Saidane O; Sellami M; Mahmoud I; Ben Tekaya A; Tekaya R; Abdelmoula L
    Therapie; 2018 Sep; 73(4):351-353. PubMed ID: 29373131
    [No Abstract]   [Full Text] [Related]  

  • 13. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
    Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
    Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.
    Szostak B; Machaj F; Rosik J; Pawlik A
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):617-626. PubMed ID: 32500745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Behrens F; Koehm M; Burkhardt H
    Curr Opin Rheumatol; 2011 May; 23(3):282-7. PubMed ID: 21427581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
    Taniguchi A; Kamatani N
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():686-90. PubMed ID: 15799443
    [No Abstract]   [Full Text] [Related]  

  • 17. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?
    Romão VC; Lima A; Bernardes M; Canhão H; Fonseca JE
    Immunol Res; 2014 Dec; 60(2-3):289-310. PubMed ID: 25391609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonitis induced by methotrexate in a patient with seronegative rheumatoid arthritis.
    Fernández Matilla M; Fernández-Llanio Comella N; Castellano Cuesta JA
    Reumatol Clin; 2015; 11(3):190-1. PubMed ID: 25631247
    [No Abstract]   [Full Text] [Related]  

  • 19. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis.
    Tian H; Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65(3):168-73. PubMed ID: 17922664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate use in rheumatoid arthritis.
    O'Dell JR
    Rheum Dis Clin North Am; 1997 Nov; 23(4):779-96. PubMed ID: 9361155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.